Article Text

other Versions

PDF
Tissue engineering of blood vessels in cardiovascular disease: moving towards clinical translation
  1. Brooks V Udelsman1,
  2. Mark W Maxfield2,
  3. Christopher K Breuer3
  1. 1Interdepartmental Program in Vascular Biology and Therapeutics, Yale University School of Medicine, New Haven, Connecticut, USA
  2. 2Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA
  3. 3Department of Surgery, Nationwide Children's Hospital, Columbus, Ohio, USA
  1. Correspondence to Dr Christopher K Breuer, Department of Surgery, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH 43205, USA; christopher.breuer{at}nationwidechildrens.org

Abstract

Tissue engineering focuses on the construction of three-dimensional neotissues from their cellular components. Neotissue can be used to repair or replace tissues that are missing, damaged, or diseased. Despite its relative youth, the field has undergone significant growth. Vascular tissue engineering is at the forefront in the translation of this technology, as tissue engineered vascular grafts have already been successfully implanted in children with congenital heart disease. The purpose of this report is to review the advances in the understanding of tissue engineered vascular grafts as the technology moves to clinical translation.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.